Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Mar;46(3):909-12.
doi: 10.1128/AAC.46.3.909-912.2002.

Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates

P Richard Harrigan  1 , Brendan A Larder
Affiliations

Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates

P Richard Harrigan et al. Antimicrob Agents Chemother. 2002 Mar.

Abstract

The phenomenon of cross-resistance to antiretroviral agents used to treat human immunodeficiency virus type 1 infection is well known but so far has been only qualitatively described. Here, we quantitate the degree of cross-resistance among all commonly prescribed antiretroviral agents in almost 5,000 clinically derived recombinant isolates collected in the United States since January 2000.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Relationships among antiretroviral drug susceptibilities within available drug classes in recent clinical isolates. The observed fold changes in susceptibility for over 4,900 clinically derived recombinant HIV-1 isolates are shown on a log-log scale for each of three drug classes, PI (A), NRTI (B), and NNRTI (C), in comparison to indinavir, zidovudine, and efavirenz susceptibility, respectively, used as representative examples.
FIG. 1.
FIG. 1.
Relationships among antiretroviral drug susceptibilities within available drug classes in recent clinical isolates. The observed fold changes in susceptibility for over 4,900 clinically derived recombinant HIV-1 isolates are shown on a log-log scale for each of three drug classes, PI (A), NRTI (B), and NNRTI (C), in comparison to indinavir, zidovudine, and efavirenz susceptibility, respectively, used as representative examples.
FIG. 1.
FIG. 1.
Relationships among antiretroviral drug susceptibilities within available drug classes in recent clinical isolates. The observed fold changes in susceptibility for over 4,900 clinically derived recombinant HIV-1 isolates are shown on a log-log scale for each of three drug classes, PI (A), NRTI (B), and NNRTI (C), in comparison to indinavir, zidovudine, and efavirenz susceptibility, respectively, used as representative examples.
See this image and copyright information in PMC

References

    1. Deeks, S. G. 2001. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):S25-S33. - PubMed
    1. Hanna, G. J., and R. T. D'Aquila. 1999. Antiretroviral drug resistance in HIV-1. Curr. Infect. Dis. Rep. 1:289-297. - PubMed
    1. Hertogs, K., M.-P. de Béthune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276. - PMC - PubMed
    1. Kaplan, J. E., D. Hanson, M. S. Dworkin, T. Frederick, J. Bertolli, M. L. Lindegren, S. Holmberg, and J. L. Jones. 2000. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30(Suppl. 1):S5-S14. - PubMed
    1. Loveday, C. 2001. Nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):S10-S24. - PubMed

Substances